scholarly journals Breast Cancer Combined with Contralateral Neck Lymph Node Metastasis. Case Report

2021 ◽  
Author(s):  
Xiaoxiao Zhong ◽  
Fengjiao Ding ◽  
Liyuan Qian ◽  
Wei Wu ◽  
Yanguang Wen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Clinical Stage ◽  
Pathological Examination ◽  
Cervical Lymph Nodes ◽  
Neck Lymph Node ◽  
Node Metastasis ◽  
Neck Lymph Node Metastasis ◽  
The Right

Abstract Background: Contralateral neck lymph node metastasis is rare for primary breast cancer. Its clinical stage and treatment principles are lack of authoritative guidelines. A 30-year-old breast cancer patient with contralateral neck lymph node metastasis is presented. The clinical treatment is discussed combined with current research.Case presentation: A 30-year-old woman presented with a right breast mass for 5 months and left neck lymph node enlargement for 5 days. The mammography showed a 33mm*14.3mm mass in the inner quadrant of right breast. The ultrasound showed several hypoechoic nodules on the left side of the neck. Rapid intraoperative pathological examination diagnosed right breast malignant tumor and poorly differentiated carcinoma of the left cervical lymph nodes. Then the right mastectomy was performed immediately. The patient was scheduled to administer chemotherapy, molecular targeted therapy, radiotherapy and endocrinotherapy after operation. The long-term efficacy remains to be seen.Conclusion: The infrequent presentation of breast cancer with metastasis to the contralateral neck lymph node can be challenged for standard therapies.

Xeroderma pigmentosum: neck lymph node metastasis of a squamous cell carcinoma of the skin treated with cetuximab

2009 ◽  
Vol 19 (2) ◽  
pp. 163-165 ◽  
Author(s):  
Jordi Rubió Casadevall ◽  
Begoña Graña-Suárez ◽  
Xavier Hernandez-Yagüe ◽  
Jordi Vayreda Ribera ◽  
Oscar Huc Grasa ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Xeroderma Pigmentosum ◽  
Neck Lymph Node ◽  
Node Metastasis ◽  
Neck Lymph Node Metastasis

Young Age and Male Sex Are Predictors of Large-Volume Central Neck Lymph Node Metastasis in Clinical N0 Papillary Thyroid Microcarcinomas

Thyroid ◽  
2017 ◽  
Vol 27 (10) ◽  
pp. 1285-1290 ◽  
Author(s):  
Hye-Seon Oh ◽  
Suyeon Park ◽  
Mijin Kim ◽  
Hyemi Kwon ◽  
Eyun Song ◽  
...  
Keyword(s):  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Large Volume ◽  
Young Age ◽  
Central Neck ◽  
Papillary Thyroid ◽  
Neck Lymph Node ◽  
Node Metastasis ◽  
Neck Lymph Node Metastasis ◽  
Male Sex

scholarly journals The Association between ANXA2 mutations and Clinical Pathological Features in Patients with Breast Cancer

2021 ◽  
Author(s):  
Jiayou Liu ◽  
Shaoli Xie ◽  
Linglong Mo ◽  
Lulan Pu ◽  
Mingfei Xu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Molecular Subtype ◽  
Clinical Stage ◽  
Missense Mutations ◽  
Early Screening ◽  
Tissue Samples ◽  
Node Metastasis ◽  
Cancer Tissues

Abstract Background Genetic mutations have been reported in many tumors. In this study, we aimed to examine whether ANXA2 mutations occur in breast cancer and to investigate their association with clinicopathological characteristics in patients. Materials and Methods We collected breast cancer and adjacent normal tissue samples from 112 patients, extracted total RNA, and performed PCR-SSCP and bidirectional Sanger sequencing. ANXA2 mutations were identified by NCBI BLAST (blastn and blastx), and their correlation with clinical data were analyzed. Results ANXA2 mutations were detected in breast cancer tissues (missense mutations 38.39%) at a higher incidence than in adjacent normal tissues (missense mutations 8.04%) and mainly located in domain and repeats 1. Moreover, mutations in breast cancer tissues were associated with clinical stages, molecular subtype, ER, PR, and lymph-node metastasis of patients. Within a mean follow-up time of 52.5 months, the 5-year OS of patients with missense mutations was lower than those without. Among those mutations, c.(350AG > GA), c.(375G > A), c.(487T > A) and c.(693G > A) were associated with younger patients. c.(350AG > GA) was related to higher clinical stage and lymph-node metastasis. c.(375G > A) was linked to HER2(-) cases, while c.(693G > A) tended to be TNBC cases. Conclusion ANXA2 missense mutations mainly occurred on domain and repeats 1 in breast cancer, which may be associated with pathogenesis, clinical stage, molecular subtyping, lymph node metastasis and 5-year OS of breast cancer. These mutations may contribute to the early screening, diagnosis, and targeted treatment of breast cancer.

scholarly journals Peri-tumoral Lymphovascular density by antipodoplanin antibody D2-40, as a predictor of nodal metastasis in oral squamous cell carcinoma

The Physician ◽  
2020 ◽  
Vol 6 (3) ◽  
pp. 1-11
Author(s):  
Kunwar Parvez ◽  
Vipin Arora ◽  
Neelam Wadhwa
Keyword(s):  
Squamous Cell Carcinoma ◽  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Oral Cancer ◽  
Oral Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Tumor Site ◽  
Neck Lymph Node ◽  
Node Metastasis ◽  
Neck Lymph Node Metastasis

BACKGROUND: The involvement of regional lymph nodes by cancer is a major determinant of prognosis in oral squamous cell carcinoma (OSCC) and is a significant predictor of patient survival. Peri-tumoral lymphangiogenesis is being studied as an important tool in predicting neck lymph node metastasis. Podoplanin, a transmembrane glycoprotein is expressed on lymphatic vessel endothelium and considered as a marker of lymphangiogenesis.  The high podoplanin expression has been associated with invasion, progression, and metastasis of oral cancer. D2-40, an anti-podoplanin monoclonal antibody, is a specific marker of lymphatic endothelial cells. The present study was designed to investigate the peritumoral lymphovascular density (PT-LVD) by evaluating D2-40 expression and its potential utility in predicting lymph node metastasis in OSCC. METHODS: Seventy-two patients with OSCC were enrolled (36 with early and 36 with advanced-stage tumors). Differential expression of peritumoral lymphovascular density (PT-LVD) was evaluated using D2-40 expression by immunohistochemistry (IHC). Expression was categorized as low and high, derived from the mean of a number of vessels per 10 high power fields in hot-spots. Statistical methods were employed to correlate expression with age, gender, tumor site, stage, and neck lymph node involvement.  RESULTS: We observed a significant association between peritumoral lymphovascular density (PT-LVD) with clinical neck lymph node status (p=0.001) and tumor stage (p=0.033).  There was no significant correlation of D2-40 expression with age, gender, tumor site, T stage, and tumor differentiation. CONCLUSION:  PT-LVD is a positive predictor of neck lymph node metastasis. It has translational potential, along with other clinical parameters for decision making in the treatment of the neck in oral cancer.

Sign in / Sign up

Export Citation Format

Share Document